

SUPPLEMENTARY TABLE S2. ASSOCIATION OF HASHIMOTO'S THYROIDITIS AND DIFFERENTIATED THYROID CANCER

| | <i>Non-DTC n (%)</i> | <i>DTC n (%)</i> | <i>Total n (%)</i> | <i>Relative risk (95% CI)</i> |
|-----------------------|------------------------|------------------|--------------------|-------------------------------|
| Non-HT | 1482 (84) | 188 (16) | 1770 (100) | — |
| Euth-HT | 183 (68) | 88 (32) | 271 (100) | 1.16 (1.10–1.23) ^a |
| Hypo-HT | | | | |
| LT ₄ -Low | 27 (57) ^b | 20 (43) | 47 (100) | 1.05 (1.02–1.08) ^a |
| LT ₄ -Mid | 44 (85) ^{b,c} | 8 (15) | 52 (100) | 1.00 (0.98–1.02) |
| LT ₄ -High | 48 (84) ^{b,c} | 9 (16) | 57 (100) | 1.00 (0.98–1.02) |

Relative risk is calculated compared to the Non-HT group.

^aFisher's exact test $p < 0.001$.

^bFisher's exact test $p < 0.05$ vs. Euth-HT.

^cFisher's exact test $p < 0.001$ vs. LT₄-Low.

Non-HT, subjects without Hashimoto's thyroiditis; Euth-HT, euthyroid patients with Hashimoto's thyroiditis; Hypo-HT, hypothyroid patients with Hashimoto's thyroiditis; LT₄, hypothyroid patients on levothyroxine replacement; Low/Mid/High, tertiles of levothyroxine replacement dose; DTC, differentiated thyroid cancer (see text for details); CI, confidence interval.